NHS England Backs Biosimilar-To-Biosimilar Switching As It Counts Adalimumab Savings

Switching between biosimilars does not appear to raise safety concerns, according to NHS England, which is anticipating more than £300m in annual savings from biosimilar competition on adalimumab.

Arrows
Multiple switches between biosimilars do not raise safety concerns. NHS England has stated in a briefing document on adalimumab • Source: Shutterstock

Real-world evidence shows that switching between biosimilars does not raise safety or efficacy concerns, a National Health Service briefing document on adalimumab has advised prescribers. By using the best-value adalimumab product available, NHS England expects to save more than £300m ($370m) in its current financial year, equivalent to about three-quarters of its historical spending on reference brand Humira.

An updated briefing by NHS England’s Regional Medicines Optimisation Committee recognizes the theoretical concerns around immunogenicity with biosimilar-to-biosimilar switching. It...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.